# US 2013/0280720 A1 · Tissue biomarkers for indication of progression from barrett's esophagus to esophageal adenocarcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280720 A1
- Document ID: US20130280720A1
- Status: Published application
- Kind: A1
- Application number: 13/798,932
- Filed: 2013-03-13
- Published: 2013-10-24
- Earliest claimed: 2012-03-15
- Assignees: University of Kansas
- Applicants: The University of Kansas
- Inventors: Lane Kevin Christenson; Ajay Bansal; Prateek Sharma
- Web page: https://patentgrep.com/patent/US20130280720A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A method of diagnosing progression from Barrett's esophagus toward esophageal dysplasia can include: obtaining miRNA from a test subject having Barrett's esophagus; assaying for miRNA biomarker selected from one or more of miR-15b or miR-486-5p; and determining whether one or more of miR-15b or miR-486-5p provide an indication of progression toward esophageal dysplasia in the test subject. The method can include determining an amount of one or more of miR-15b or miR-486-5p. The method can include determining a modulation in amount of one or more of miR-15b or miR-486-5p. The method can include comparing the one or more of miR-15b or miR-486-5p with a positive control or a negative control.

## Claims

### Claim 1

A method of diagnosing progression from Barrett's esophagus toward esophageal dysplasia, the method comprising:
obtaining miRNA from a test subject having Barrett's esophagus;
assaying for miRNA biomarker selected from one or more of miR-15b or miR-486-5p; and
determining whether one or more of miR-15b or miR-486-5p provide an indication of progression toward esophageal dysplasia in the test subject.

### Claim 2 (depends on 1)

The method of claim 1, comprising determining an amount of one or more of miR-15b or miR-486-5p.

### Claim 3 (depends on 1)

The method of claim 1, comprising determining a modulation in amount of one or more of miR-15b or miR-486-5p.

### Claim 4 (depends on 1)

The method of claim 1, comprising comparing the one or more of miR-15b or miR-486-5p with a positive control or a negative control, the positive control being from a subject having esophageal dysplasia, the negative control being from a subject without esophageal dysplasia.

### Claim 5 (depends on 4)

The method of claim 4, wherein if one or more of the miR-15b or miR-486-5p is similar to the positive control or different from the negative control, there is an indication of esophageal dysplasia in the test subject.

### Claim 6 (depends on 4)

The method of claim 4, wherein if one or more of the miR-15b or miR-486-5p is similar to the negative control or different from the positive control, there is an indication of esophageal dysplasia in the test subject.

### Claim 7 (depends on 1)

The method of claim 1, comprising:
assaying for miRNA biomarker selected from one or more of miR-21, miR-145, miR-203, or miR-let-7a; and
determining whether one or more of miR-21, miR-145, miR-203, or miR-let-7a provide an indication of esophageal dysplasia in the test subject.

### Claim 8 (depends on 1)

The method of claim 1, wherein the assaying includes contacting the miRNA biomarker with a complement thereof.

### Claim 9 (depends on 8)

The method of claim 8, comprising performing RT-PCR with one or more primers for the miRNA biomarker.

### Claim 10 (depends on 8)

The method of claim 8, comprising the complement of the miRNA biomarker being located on a diagnostic chip.

### Claim 11 (depends on 1)

The method of claim 1, comprising:
diagnosing esophageal dysplasia in the test subject.

### Claim 12 (depends on 1)

The method of claim 1, comprising:
diagnosing esophageal cancer in the test subject.

### Claim 13

A method of detecting progression from Barrett's esophagus toward dysplasia, the method comprising:
obtaining miRNA from a test subject;
assaying for a plurality of miRNA biomarkers selected from the group consisting of miR-15b, miR-486-5p, miR-21, miR-145, miR-203, or miR-let-7a; and
determining whether the assayed plurality of miRNA selected from the group consisting of miR-15b, miR-486-5p, miR-21, miR-145, miR-203, or miR-let-7a provide an indication of progression toward dysplasia in the test subject.

### Claim 14 (depends on 13)

The method of claim 13, comprising determining an amount or modulation of the assayed plurality of miRNA selected from the group consisting of miR-15b, miR-486-5p, miR-21, miR-145, miR-203, or miR-let-7a.

### Claim 15 (depends on 13)

The method of claim 13, comprising:
comparing the assayed plurality of miRNA selected from the group consisting of miR-15b, miR-486-5p, miR-21, miR-145, miR-203, or miR-let-7a with a positive control or a negative control, the positive control being from a subject having dysplasia, the negative control being from a patient without dysplasia,
wherein if one or more of the miR-15b or miR-486-5p is similar to the positive control or different from the negative control, there is an indication of progression toward dysplasia in the test subject; or
if one or more of the miR-15b or miR-486-5p is similar to the negative control or different from the positive control, there is an indication of progression toward dysplasia in the test subject.

### Claim 16 (depends on 13)

The method of claim 13, comprising:
diagnosing esophageal dysplasia in the test subject.

### Claim 17 (depends on 13)

The method of claim 13, comprising:
diagnosing esophageal cancer in the test subject.

### Claim 18

A diagnostic kit comprising:
a plurality of polynucleotides selected from the group consisting of miR-15b, miR-486-5p, miR-21, miR-145, miR-203, miR-let-7a, or compliment thereof.

### Claim 19 (depends on 15)

The diagnostic kit of claim 15, comprising one or more of:
miR-15b or complement thereof or miR-486-5p or complement thereof.

### Claim 20 (depends on 18)

The diagnostic kit of claim 18, the plurality of nucleotides including one or more primers for two or more of miR-15b, miR-486-5p, miR-21, miR-145, miR-203, or miR-let-7a.

### Claim 21 (depends on 18)

The diagnostic kit of claim 18, the plurality of nucleotides including a compliment polynucleotide for two or more of miR-15b, miR-486-5p, miR-21, miR-145, miR-203, or miR-let-7a.

### Claim 22 (depends on 21)

The diagnostic kit of claim 21, a chip having the plurality of compliment nucleotides for two or more of miR-15b, miR-486-5p, miR-21, miR-145, miR-203, or miR-let-7a.
